FDA Clears First Blood Tests for Earlier Alzheimer’s Diagnosis
The U.S. Food and Drug Administration has cleared new blood-based biomarker tests, including the PrecivityAD2 test and the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, designed to aid physicians in the ... Read More